December 5, 2004

Clinical Alert from the National Heart, Lung, and Blood Institute


Adobe PDF version

The National Heart, Lung, and Blood Institute (NHLBI) announced today an advisory recommending that blood transfusions should be continued in order to reduce the rate of strokes (cerebral infarctions or hemorrhages) in children with sickle cell anemia who are at risk of strokes. Strokes occur in approximately 10% of children with sickle cell anemia. These cerebral vascular events can be very debilitating, leading to physical and neuro-psychological impairment which can affect motor skills, school performance, and overall quality of life.

In 1997, a Clinical Alert was issued by NHLBI based on the Stroke Prevention Trial in Sickle Cell Anemia (STOP I) Trial. In that study, a 90% reduction in the rate of first-time stroke was reported when chronic blood transfusions were offered to children with sickle cell anemia who had been identified as being at high risk by transcranial Doppler (TCD). Periodic red blood cell transfusions reduced the rate of stroke by 90 % in STOP I. By lowering the level of hemoglobin S (Hb S) below 30%, strokes were prevented in children found to be at increased risk by virtue of having elevated transcranial doppler (TCD) velocities in the internal carotid and middle cerebral arteries.

In 2000, a second randomized, controlled clinical trial, STOP II, funded by NHLBI, was initiated to test whether chronic transfusions for primary stroke prevention could be safely discontinued after at least 30 months (range 30 - 91 months) in children who had not had an overt stroke, and who had reversion to low risk TCD velocity with chronic transfusion therapy. Low risk TCD velocity is defined as <170 cm/sec time averaged mean of the maximum. The purpose of the STOP II trial was to optimize transfusion for stroke prevention by determining which children needed continued therapy to prevent stroke. Chronic blood transfusion therapy is costly and can be associated with significant morbidities including risk of iron overload, alloimmunization, and exposure to infectious blood borne agents.

The STOP II Trial showed that when transfusions were discontinued after a minimum of 30 months, a significant number of children reverted to high risk range of TCD velocities or, in the case of two children, developed an overt stroke after an elevated TCD velocity was observed.

The STOP II Trial, headquartered at the Medical College of Georgia (Dr. Robert Adams) and the New England Research Institutes (Dr. Donald Brambilla), enrolled 79 children who ranged from 2 to 18 years of age. The patients were drawn from 23 clinical centers in the United States and two in Canada (list attached). The patients were randomized to receive either standard supportive care with periodic blood transfusions or to be withdrawn from periodic blood transfusions if their TCD velocity had returned to low-risk range. Children with severe stenosis of the middle cerebral or internal carotid arteries viewed by magnetic resonance angiography (MRA) were excluded from randomization. The primary endpoint was the comparison of the rate of reversion to abnormal TCD velocity and/or stroke in the treated and control groups.

In both treatment arms, children received close clinical and TCD surveillance for the first occurrence of reversion of TCD to abnormal, confirmed with two or more TCD’s of 200 cm/sec or higher. This TCD change indicated a return of high risk for overt stroke. In addition, overt stroke was included as part of the primary endpoint. The main hypothesis was that over 3 years of observation fewer than 50% of children in the experimental arm would revert to high stroke risk or have an overt stroke, and that quarterly (at least every 8 to 12 weeks) surveillance with TCD would provide acceptable safety monitoring with respect to stroke risk.

The patients in the transfusion arm received periodic simple or exchange blood transfusions every 3 to 4 weeks in an effort to maintain the Hb S level below 30%. The trial protocol required that red blood cell transfusions were matched for ABO, C, D, E, and K antigens. The children in both arms were followed for exposure to transfusion transmitted viral diseases and iron overload. Patients who had been on the transfusion protocol and received a cumulative dose of 250 ml/kg of blood began to develop elevated serum ferritin levels greater than 2500 mg/L and were started on chelation therapy.

After 79 of a planned sample size of 100 children were randomized, the Data and Safety Monitoring Board, appointed by NHLBI, recommended closure of the study for safety concerns when an interim analysis showed a highly significant difference between the transfusion and non-transfusion treatment arms with respect to the composite endpoint of TCD reversion to high risk and overt stroke. At the time of closure of the trial, in 41 subjects randomized to come off transfusion, there had been 16 endpoints. Of the 16 endpoints, 14 reversions to high risk TCD (without stroke) occurred, and two ischemic strokes occurred shortly after the first TCD reverted to abnormal but before a confirmatory TCD could be obtained and transfusion therapy resumed. Six other subjects were returned to periodic transfusion therapy for clinical reasons before endpoints occurred (crossovers), primarily due to recurrent acute chest syndrome or sickle cell related painful episodes.

No neurologic events or reversions to high risk TCD were observed in those subjects who were in the chronic transfusion treatment arm. The reversions to abnormal TCD velocity were seen early after discontinuation of periodic transfusions, between 4-9 months. The length of time on transfusion therapy prior to randomization was the only potential indicator of TCD reversion to abnormal that was identified by secondary analyses. There was a trend toward lower risk of reversion to abnormal TCD in subjects who were transfused for greater than 54 months prior to randomization. Age, gender, presence of silent infarct lesions on magnetic resonance imaging, %Hb S on transfusion, and number of transfusions prior to randomization did not predict increased risk of reversion to abnormal TCD.

While some children tolerate removal from chronic transfusion therapy without apparent problems, discontinuation of transfusion after 30 months cannot be recommended based on STOP II due to the high TCD reversion rate, and the small risk of overt stroke despite frequent TCD surveillance. In addition, there is the likelihood that some children may need to return to transfusions for other sickle cell related clinical reasons.

It should be emphasized that the patients studied in STOP II were those with TCD velocities that reverted to low risk on periodic transfusions, and without severe arterial lesions on MRA. This subset of children who participated in STOP II are thought to be at lower risk for stroke than those children who had been in STOP I but did not qualify for STOP II because their TCD velocities did not revert to normal on transfusions or because they had arterial lesions on MRA.

Further research will be needed to: (1) determine better ways to predict those who can be removed safely from transfusion while still accomplishing effective primary stroke prevention, or (2) identify and test alternative therapies to transfusion that will provide safe and effective protection from stroke with fewer side effects than transfusion. Physicians will have to carefully discuss with patients and their families the risk-benefit ratio of continuing periodic transfusions for stroke prevention when compared to the long term side effects of iron overload. The choice of clinical management, including whether to continue periodic transfusions or to stop transfusions with TCD monitoring every 2-3 months, must be made on a case-by-case basis. Children who continue on chronic transfusions should also receive appropriate management of iron overload.

STOP II Principal Investigators as of November 02, 2004

Robert J. Adams, MS, MD (Principal Investigator Clinical Consortium)
Regents Professor of Neurology
Medical College of Georgia
1429 Harper Street, HF 1154
Augusta, GA 30912
Phone 706-721-4670
Fax 706-721-6950
Email rjadams@mcg.edu

Donald J. Brambilla, PhD (Principal Investigator Data Coordinating Center)
New England Research Institutes
9 Galen Street
Watertown, MA 02172
Phone 617-923-7747 X 230
Fax 617-926-8246
Email donb@neri.org

STOP II PERIPHERAL SITE INVESTIGATORS

Alvarez, Ofelia, MD
Jackson Memorial Hospital
1611 NW 12th Avenue
ACC West R-555
Miami, FL 33136
Phone 305-585-5635
Fax 305-545-8387
Email oalvarez2@med.miami.edu

Barredo, Julio MD
Medical University of South Carolina
135 Rutledge Avenue
Charleston, SC 29425
Phone 843-792-2957
Fax 843-792-8912
Email barredjc@musc.edu

Berman, Brian MD
Rainbow Babies & Children’s Hospital
Ped/Hem/Onc
11100 Euclid Avenue, Room 310
Cleveland, OH 44106
Phone 216-844-3345
Fax 216-844-5431
Email brian.berman@uhhs.com

Casella, James MD
Johns Hopkins University
School of Medicine
720 Rutland Avenue, Ross 1125
Baltimore, MD 21205
Phone 410-955-6132
Fax 410-955-8208
Email jcasella@jhmi.edu

Coates, Thomas MD
Children’s Hospital of Los Angeles
University of Southern California
School of Medicine
4650 Sunset Blvd, MS 54
Los Angeles, CA 90027
Phone 323-669-2352
Fax 323-660-9321
Email tcoates@hsc.usc.edu

Daeschner, Charles MD
Director of Pediatric Hematology/Oncology
Associate Professor of Pediatrics
School of Medicine, Dept. of Pediatrics
East Carolina University
Brody Medical Sciences Building
600 Moye Boulevard
Greenville, NC 27858
Phone 252-816-4676 or 4151
Fax 252-816-8199
Email daeschnerc@mail.ecu.edu

Driscoll, Catherine MD
Children’s National Medical Center
Dept. Hem/Onc
111 Michigan Avenue NW
Washington, DC 20010
Phone 202-884-2867
Fax 202-884-5685
Email cdriscol@cnmc.org

Files, Beatrice MD
Scottish Rite Children’s Medical Center
5455 Meridian Mark Rd #400
Atlanta GA 30342
Phone 404-785-3634
Fax 404-785-3520
Email beatrice.files@choa.org

Gee, Beatrice MD
Assistant Professor of Clinical Pediatrics
Morehouse School of Medicine
Dept. of Pediatrics
720 Westview Drive, SW
Atlanta GA 30310
Phone 404-756-1335 (gen office: 756-1330)
Fax 404-756-1357
Email geeb@msm.edu

Hilliard, Lee MD
Assistant Professor of Pediatrics
University of Alabama at Birmingham
Pediatric Sickle Cell Center
1600 7th Avenue South CHT 651
Birmingham AL 35233
Phone 205-939-9285
Fax 205-975-6377
Email lhilliard@peds.uab.edu

Iyer, Rathi MD
The University of Mississippi Medical Center Children’s Hospital
Division of Pediatric Hematology/Oncology
2500 N State Street
Jackson MS 39216
Phone 601-984-5220
Fax 601-984-5279
Email riyer@ped.umsmed.edu

Kalinyak, Karen MD
Children’s Hospital Medical Center
Hematology/Oncology Division
3333 Burnet Avenue
Cincinnati OH 45036
Phone 513-636-4379
Fax 513-636-5845
Email karen.kalinyak@chmcc.org

Kirby, Melanie MD
The Hospital for Sick Children
555 University Avenue
Hem/Onc
Toronto, Ontario
Canada M5G1X8
Phone 416-813-7606
Fax 416-813-5759
Email melanie.kirby@sickkids.on.ca

Kwiatkowski, Janet MD
Children’s Hospital of Philadelphia
Division of Hematology
Wood Bldg 4th Floor
34th Street and Civic Center Boulevard
Philadelphia PA 19104
Phone 215-590-3681
Fax 215-590-3992
Email kwiatkowski@email.chop.edu

Lane, Peter MD
Emory University
Dept. Hem/Onc
2040 Ridgewood Drive, NE
Suite 106
Atlanta, GA 30322
Phone 404-727-1288
Fax 404-727-4455
Email plane@emory.edu

McKie, Virgil MD
Medical College of Georgia
The Marks Building, HF 1107
1429 Harper Street
Augusta, GA 30912
Phone 706-721-3626
Fax 706-721-2643
Email vmckie@deptpeds.mcg.edu

Miller, Scott MD
SUNY-Brooklyn
Kings County Hospital
450 Clarkson Avenue, Box 49
Brooklyn, NY 11203
Phone 718-270-1692
Fax 718-270-1985
Email stmseelig@aol.com

Olivieri, Nancy MD
University Health Network
Toronto General Hospital
200 Elizabeth Street, CW-3-338
Toronto, Ontario
Canada M5G 2C4
Phone 416-340-4800 ext 6507
Fax 416-340-3348
Email noliv@attglobal.net

Piomelli, Sergio MD
Columbia University
3959 Broadway BHB Room 21
New York, NY 10032
Phone 212-305-6538
Fax 212-305-8408
Email sp23@columbia.edu

Provisor, Arthur MD
Columbus Regional Hospital
710 Center Street
Columbus, GA 31902
Phone 706-571-1221
Fax 706-571-1070
Email arthur.provisor@chrs.net

Vichinsky, Elliott MD
Children’s Hospital Oakland
747 52nd Street, Dept. Hematology
Oakland, CA 94609
Phone 510-428-3651
Fax 510-450-5647
Email evichinsky@mail.cho.org

Wang, Winfred MD
St. Jude Children’s Research Hospital
332 North Lauderdale St
Ped/Hem/Onc
Memphis, TN 38105
Phone 901-495-3497
Fax 901-521-9005
Email win.wang@stjude.org

Wiley, Joseph MD
Sinai Hospital of Baltimore
2401 W. Belvedere Avenue
Baltimore, MD 21215
Phone 410-601-5864
Fax 410-601-8390
Email jwiley@lifebridgehealth.org

Woods, Gerald MD
Children’s Mercy Hospital
2401 Gilham Road
Hem/Onc
Kansas City, MO 64108
Phone 816-234-3265
Fax 816-471-5460
Email gwoods@cmh.edu

Warrier, Raj MD
Children’s Hospital of New Orleans
Louisiana State University Medical Center
Dept. Ped/Hem/Onc
1542 Tulane Avenue
New Orleans, LA 70112
Phone 504-896-9740
Fax 504-896-9758
Email rwarri@lsuhsc.edu




Skip footer links and go to content

Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon